Pyrimidineamide derivatives and the use thereof

Details Pyrimidineamide derivatives and the use thereof Pyrimidineamide derivatives and the use thereof

2003-09-26

2010-02-02

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S324000

Reexamination Certificate

active

07655669

ABSTRACT:
The invention relates to novel substituted N-(3-benzoylaminophenyl)-4-pyridyl-2-pyrimidinamine derivatives, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, and a method for the treatment of such a disease.

REFERENCES:
patent: 5215989 (1993-06-01), Baldwin et al.
patent: 5516775 (1996-05-01), Zimmermann et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 0 233 461 (1987-08-01), None
patent: 0 564 409 (1993-10-01), None
patent: 0 588 762 (1994-03-01), None
patent: 2 369 359 (2002-05-01), None
patent: 0 564 409 (1993-10-01), None
patent: WO 95/09847 (1995-04-01), None
patent: WO 95/09852 (1995-04-01), None
patent: WO 01/47507 (2001-07-01), None
patent: WO 01/64200 (2001-09-01), None
patent: 02 22597 (2002-03-01), None
patent: WO 02/22597 (2002-03-01), None
patent: 02 93164 (2002-11-01), None
patent: WO 02/093164 (2002-11-01), None
Traxler, Protein Tyrosine Kinase inhibitors in Cancer treatment, Expert Opinion on Therapeutic Patents, 7(6), pp. 571-588, 1997.
Yano et al., Medline Abstract (Clinical Cancer Research, vol. 6, Issue 3, pp. 957-965), Mar. 2000.
Cressey et al., Medline Abstract (BMC Cancer, vol. 5, p. 128) Oct. 2005.
Simone, Onclogy: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Buchdunger et al., “Selective Inhibition of the Platelet-Derived Growth Factor Signal Transduction Pathway by a Protein-Tyrosine Kinase Inhibitor of the 2-Phenylaminopyrimidine Class”,Proc Natl Acad Sci USA, vol. 92, No. 7, pp. 2558-2562 (1995).
Buchdunger et al., “Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative”,Cancer Res, vol. 56, No. 1, pp. 100-104 (1996).
Carroll et al., “CGP 57148, A Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins”,Blood, vol. 90, No. 12, pp. 4947-4952 (1997).
Druker et al., “Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells”,Nat Med, vol. 2, No. 5, pp. 561-566 (1996).
Druker et al., “Selective Killing of Bcr-Abl Positive Cells with a Specific Inhibitor of the Abl Tyrosine Kinase”, Pezcoller Foundation Symposia,Cancer Genes, pp. 255-267 (1996).
Zimmermann et al., “Phenylamino-Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)”,Arch Pharm Pharm Med Chem, vol. 329, No. 7, pp. 371-376 (1996).
Zimmermann et al., “Phenylamino-Pyrimidine (PAP)—Derivatives: A New Class of Potent and Highly Selective PDGF-Receptor Autophosphorylation Inhibitors”,Bioorg Med Chem Lett, vol. 6, No. 11, pp. 1221-1226 (1996).
Zimmermann et al., “Potent and Selective Inhibitors of the Abl-Kinase: Phenylamino-Pyrimidine (PAP) Derivatives”,Bioorg Med Chem Lett, vol. 7, No. 2, pp. 187-192 (1997).

Affiliated with

Also associated with

Rating

Pyrimidineamide derivatives and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrimidineamide derivatives and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidineamide derivatives and the use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4226441